SYGNIS AG

EANS-Adhoc: SYGNIS Pharma AG
SYGNIS Pharma AG secures further financial resources with shareholder loan


--------------------------------------------------------------------------------
  ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro
  adhoc with the aim of a Europe-wide distribution. The issuer is solely
  responsible for the content of this announcement.
--------------------------------------------------------------------------------
Capital measures
04.03.2013


Ad hoc-Release according to § 15 WpHG
      
SYGNIS Pharma AG secures further financial resources with shareholder loan

Heidelberg 4 March 2013 - SYGNIS Pharma AG (Frankfurt: LIO1; ISIN: DE000A1RFM03,
Prime Standard) today reports on the granting of a shareholder loan for a total
amount of up to EUR 0.7 million by its main shareholders Genetrix Life Sciences,
A.B., Uppsala (Sweden) and dievini Hopp BioTech holding GmbH & Co. KG, Walldorf
(Germany) with an interest-rate at customary market conditions. As a result this
loan, which is payable on demand and subject to a condition precedent, secures
the financing of SYGNIS' existing operations, according to the present plans,
until mid 2013. The loan is unsecured and is due for repayment not before the
end of 2015. 

**** end of ad hoc ****


For further information please contact:


SYGNIS Pharma AG                        
Peter Willinger
CFO                     

Tel: +49 6221 454 836                   
Email: willinger@sygnis.de
                


### Disclaimer
This publication is intended for information only and constitutes neither an
offer to sell nor an invitation to buy securities. Some statements included in
this press release, relating neither to proven financial results nor other
historical data, should be viewed as forward-looking, i.e. not definite. Such
statements are mainly predictions of future results, trends, plans or goals.
These statements should not be considered to be total guarantees since given
their very nature they are subject to known and unknown risks and
imponderability and can be affected by other factors as a consequence of which
the actual results, plans and goals of SYGNIS Pharma AG may deviate greatly from
the established conclusions or implied predictions contained in such statements.
SYGNIS does not undertake to publicly update or revise these statements in the
light of new information or future results or for any other reason.
###


Further inquiry note:
Marc Risch
Telefon: +49 (6221) 454 - 737
E-Mail: Marc.Risch@sygnis.de

end of announcement                               euro adhoc 
--------------------------------------------------------------------------------


issuer:      SYGNIS Pharma AG
             Im Neuenheimer Feld 515
             D-69120 Heidelberg
phone:       +49 (0)6221 454-6
FAX:         +49 (0)6221 454-777
mail:     contact@sygnis.de
WWW:      http://www.sygnis.de
sector:      Biotechnology
ISIN:        DE000A1RFM03
indexes:     CDAX, Prime All Share
stockmarkets: free trade: Hannover, Berlin, München, Hamburg, Düsseldorf,
             Stuttgart, regulated dealing/prime standard: Frankfurt 
language:   English
 

 

 



Das könnte Sie auch interessieren: